Michael Logsdon, DO
Family Medicine · Rensselaer, NYNPI 1669855235
Payments from drug & device makers
Across 77 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$627
- Lilly USA, LLC$242
- Exact Sciences$152
- AbbVie$124
- GSK$121
- Novo Nordisk$115
- plus $538 from 17 others
What the payments were for
- Food & beverage$1,919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $627 |
| Lilly USA, LLC | 12 | $242 |
| Exact Sciences | 7 | $152 |
| AbbVie | 6 | $124 |
| GSK | 7 | $121 |
| Novo Nordisk | 5 | $115 |
| Pfizer | 5 | $84 |
| Boehringer Ingelheim | 3 | $51 |
| Seqirus USA Inc | 2 | $48 |
| Sanofi Pasteur Inc. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Amgen | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Astellas Pharma US Inc | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Braeburn Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Indivior Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| SNAP Diagnostics LLC | 1 | $12 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,919 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $75,341 |
| OzempicSemaglutide | 51 | $69,087 |
| EliquisApixaban | 35 | $47,526 |
| JanuviaSitagliptin Phosphate | 31 | $35,931 |
| MounjaroTirzepatide | 24 | $24,817 |
| TrulicityDulaglutide | 17 | $19,422 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,504 |
| Atorvastatin Calcium | 489 | $7,337 |
| Novolog FlexpenInsulin Aspart | 19 | $6,095 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $4,450 |
| Levothyroxine Sodium | 274 | $4,387 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 142 | $4,327 |
| Icosapent Ethyl | 18 | $4,003 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $3,876 |
| Ezetimibe | 44 | $3,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $51 | $75,34156 claims |
| Novo NordiskOzempic | $115 | $69,08751 claims |
| PfizerEliquis | $84 | $47,52635 claims |
| Lilly USA, LLCMounjaro, Trulicity | $242 | $44,23941 claims |
| GSKTrelegy Ellipta | $121 | $13,50418 claims |
| AbbVieSynthroid | $124 | $1,04321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.
Other family medicine in Rensselaer
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.